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ttp://dx.doi.org/10.1016/j.ajpath.2013.03.013Previous studies from our laboratory have found glypican 3 (GPC3) as a negative regulator of growth.
CD81 was found to be a binding partner for GPC3, and its expression and co-localization with GPC3
increased at the end of hepatocyte proliferation. However, the mechanisms through which these two
molecules might regulate liver regeneration are not known. We tested the hypothesis that GPC3 down-
regulates the hedgehog (HH) signaling pathway by competing with patched-1 for HH binding. We found
decreased GPC3-Indian HH binding at peak proliferation in mice followed by increase in glioblastoma
1 protein (effector of HH signaling). We performed a yeast two-hybrid assay and identiﬁed hema-
topoietically expressed homeobox (Hhex, a known transcriptional repressor) as a binding partner for
CD81. We tested the hypothesis that Hhex binding to CD81 keeps it outside the nucleus. However, when
GPC3 binds to CD81, CD81-Hhex binding decreases, resulting in nuclear translocation of Hhex and
transcriptional repression. In support of this, we found decreased GPC3-CD81 binding at hepatocyte
proliferation peak, increased CD81-Hhex binding, and decreased nuclear Hhex. GPC3 transgenic mice
were used as an additional tool to test our hypothesis. Overall, our data suggest that GPC3 down-
regulates cell proliferation by binding to HH and down-regulating the HH signaling pathway and
binding with CD81, thus making it unavailable to bind to Hhex and causing its nuclear translocation.
(Am J Pathol 2013, 183: 153e159; http://dx.doi.org/10.1016/j.ajpath.2013.03.013)Supported by NIH grant 5R01CA035373-29 (G.K.M.).Glypican 3 (GPC3) is a heparan sulfate proteoglycan that is
bound to cell surface by glycosylphosphatidylinositol.1 Loss-
of-function mutations ofGPC3 result in the Simpson-Golabi-
Behmel syndrome, an X-linked disorder characterized by
prenatal and postnatal organ overgrowth, including liver.2,3
CD81, also known as target of antiproliferative antibody, is
a cell surface protein that belongs to tetraspanin 4 super-
family.4 It is involved in mediating signal transduction events
that play a role in regulation of cell development, activation,
growth, and motility.5,6 Our laboratory has previously
demonstrated that GPC3 acts as a negative regulator of liver
regeneration.7,8 This observation was accompanied by an
increase in expression and co-localization of CD81 (a
binding partner for GPC3) in tandemwith GPC3 at the end of
hepatocyte proliferation.7,8 However, the mechanisms and
pathways through which these two molecules might regulate
liver regeneration are not known.
In the present study, we sought to identify the mecha-
nisms and potential associated partners through which thesestigative Pathology.
.two proteins might mediate regulation of liver growth.
Previous literature suggests that GPC3 can bind to hed-
gehog (HH) ligands and inhibit HH signaling during
development.9 The HH signaling pathway has been previ-
ously reported to play an important role in liver regenera-
tion after partial hepatectomy (PHx) in mice.10 We tested
the hypothesis that GPC3 down-regulates the HH signaling
pathway by competing with patched-1 for HH binding to
regulate liver regeneration (Figure 1). On the other hand,
GPC3-HH binding decreases to free up HH signaling at the
time of proliferation after PHx (Figure 1). To investigate the
mechanisms for CD81’s role in regulating liver growth, we
performed a yeast two-hybrid assay to identify potential
binding partners for CD81. Hematopoietically expressed
homeobox protein (Hhex) was a CD81 binding partner
under high-stringency binding conditions. Most of the
studies describing Hhex’s role are in liver development.11,12
Figure 1 Hypothesized mechanism(s) for GPC3 as a growth regulator.
In resting liver, GPC3 regulates growth by two pathways: it competes with
patched for HH binding, thus inhibiting nuclear activation of GLI, and it
binds to CD81, thus decreasing the availability of free CD81 to bind to Hhex
and keeping it outside the nucleus. In regenerating liver, GPC3 binding to
HH and CD81 decreases, which leads to induction of HH signaling and
increased CD81-Hhex binding. Hence, GPC3 brings about increased nuclear
GLI and decreased nuclear Hhex during cell proliferation. SMO, smooth-
ened; TEM, tetraspanin enhanced microdomain.
Bhave et alHhex is expressed in some adult tissues, including liver, lung,
spleen, thymus, and pancreas.13e15 Hhex mRNA has been
previously detected in adult mouse liver and has been shown
to be a transcriptional repressor.16,17 Its role in adult liver
remains unexplored for the most part. Previous studies
suggest that the role of Hhex is dependent on its shuttling
between cytoplasm and nucleus.18 However, the mechanisms
governing its translocation into the nucleus are not known.
We hypothesized that Hhex binding to CD81 during hepa-
tocyte proliferation keeps it outside the nucleus (Figure 1).
When GPC3 binds to CD81, less CD81 is available for
binding to Hhex, resulting in nuclear translocation of Hhex,
in turn causing transcriptional repression (Figure 1). Thus,
the present study tests two mechanisms for the role of GPC3
as a growth regulator: GPC3 binds with HH ligand to
decrease HH signaling and GPC3 binds to CD81, leading to
nuclear translocation of transcriptional repressor Hhex. We
used wild-type (WT) and GPC3 transgenic (TG) mice
(previously found to exhibit decreased liver regeneration
response)8 as an additional tool to test the hypotheses.
Materials and Methods
GPC3 TG Mice
Generation of male GPC3 TG mice is described previously.8
These mice show signiﬁcant over expression of GPC3
protein and mRNA compared with their WT littermates
(friend leukemia virus B strain mice).8
Yeast Two-Hybrid Assay
The Matchmaker GAL4 yeast two-hybrid system (Clontech,
Mountain View, CA) was used for identiﬁcation of CD81-
binding partners according to standard protocol.19 As bait for154screening, the vector pGBKT7 expressing a fusion protein
composed of full-length rat CD81 cDNA linked to the DNA-
binding domain was constructed. Positive clones were
selected on SD/-Ade/-His/-Leu/-Trp high-stringency YPDA
(yeast, peptone, dextrose, adenine) plateswithX-Gal. Plasmids
from positive clones were subsequently isolated from the
yeast, transferred to Escherichia coli Top10 competent cells
(Invitrogen,Grand Island, NY), and sequenced. TheGenBank/
National Center for Biotechnology Information databases
were screened for similar sequences using BLAST search.
Protein Analysis by Western Blot
Nuclear and cytoplasmic extracts pooled from at least four
mice per time point were prepared using NE-PER nuclear
and cytoplasmic extraction kit according to the manufac-
turer’s protocol (catalog number 78833; Pierce Biotech-
nology, Rockford, IL). Solubilized protein was subjected to
Western blot analysis as described previously.20 Membranes
were stained with Ponceau stain and b-actin (for nuclear and
cytoplasmic extracts, respectively) to verify equal loading
of total protein and transfer efﬁciency. Horseradish perox-
idaseeconjugated secondary antibodies were used at a
1:50,000 dilution (Jackson Immunoresearch Laboratories,
West Grove, PA). Primary antibodies used with their
concentrations were as follows: GPC3 (ARP37665 Aviva
Systems Biology Corp., San Diego, CA, 1:1000; SC10456,
Santa Cruz Biotechnology, Dallas, TX, 1:200), CD81
(GTX75432 GeneTex, Irvine, CA, 1:1000; SC70803, Santa
Cruz, 1:500), Indian HH (IHH) (ab52919, Abcam, Cam-
bridge, MA, 1:5000), Smoothened (ab72130, Abcam,
1:2000), GLI1 (PAB10214, Abnova, Taipei City, Taiwan,
1:2000), patched-1 (ab39266, 1:2000; sc6147, 1:250), and
Hhex (CA1326, Cell Applications, San Diego, CA).
70% PHx in Mice
Isoﬂurane inhalation (Baxter, Deerﬁeld, IL) was used to
anesthetize mice. PHx was performed on at least four mice
per group per time point as described previously.21 Liver
tissue samples from GPC3 TG and WT (littermates) were
collected on day 0 (baseline), day 2 (proliferation peak), and
day 8 (past end of hepatocyte proliferation) after PHx for
further analysis.
IHC for GLI1
Parafﬁn-embedded liver sections (4 mm thick) were used for
immunohistochemical (IHC) staining. Antigen retrieval was
achieved by steaming the slides in target retrieval buffer
(Dako, Carpinteria, CA) for 20 minutes. The tissue sections
were blocked in protein block for 20 minutes followed by
incubation with primary antibody (1:250) for 1 hour at room
temperature. The primary antibody was then linked to bio-
tinylated secondary antibody (1:250) followed by routine
avidin-biotin complex method. Diaminobenzidine was used
as the chromogen, which resulted in a brown reaction product.ajp.amjpathol.org - The American Journal of Pathology
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Mouse liver tissue was homogenized in radioimmuno-
precipitation assay (RIPA) buffer with inhibitors. For
immunoprecipitation studies, 500 mg of protein lysatesThe American Journal of Pathology - ajp.amjpathol.orgpooled from at least four mice per group per time point were
diluted to a ﬁnal volume of 500 mL and precleared by
incubating with IgG from the source of primary antibody
and 20 mL of agarose A/G plus beads (Santa Cruz) for
1 hour at room temperature. Protein complexes were
immunoprecipitated from cleared lysates with primary
antibodies overnight at 4C, followed by 2-hour incubation
at 4C with agarose A/G plus beads. Immune complexes
were then collected and washed three times with RIPA
buffer containing protease and phosphatase inhibitors
(Sigma, St. Louis, MO) before resuspension in 4 SDS-
PAGE sample buffer and 10 reducing reagent (Invi-
trogen). Proteins from immunoprecipitated samples or 30 mg
of crude liver protein were separated by SDS-PAGE and
subjected to Western blotting. Note that the Western blots of
proteins that are pulled down using this technique are not
reﬂective of their absolute expression levels (that require
equal loading). Our analyses in this article rely on the ratios
of bound protein to pulled down protein, which reﬂect
changes in protein interactions.
GST Pull-Down Assay
To conﬁrm Hhex as a true binding partner for CD81 from
the yeast two-hybrid assay, we performed a glutathione S-
transferase (GST) pull-down assay. Hhex-GST fusion
protein or GST protein (control) from Proteintech (Chicago,
IL) (catalog number ag13423) was used for the pull-down
assay. The fusion protein was ﬁrst dialyzed using a 10-
kDa membrane cup to get rid of residual GSH (approxi-
mately 330 Da) that could interfere with the assay. Total cell
lysate (500 mg) pooled from four WT mice was diluted in
500 mL of RIPA buffer with protease and phosphatase
inhibitors (Sigma). GSH resin (100 mL; Thermo Scientiﬁc,
Tewksbury, MA) was applied to spin cups, centrifuged, and
washed using manufacturer instructions. Hhex-GST fusion
protein or GST protein was applied to the spin cups
immediately followed by pooled whole cell lysate from WT
mice livers. The cup was sealed, vortexed, and incubated at
4C by gentle rocking for an hour. The spin cups were
centrifuged and washed three times. Protein was eluted
using 2 sample buffer mixed with b-mercaptoethanol. The
elute was used for Western blot analysis to detect Hhex and
GST to conﬁrm pull down. The same membrane was
stripped (Sigma stripping buffer) and reprobed for CD81.Figure 2 GPC3 inhibits HH signaling pathway. A: Western blot of GPC3,
patched, and IHH after co-immunoprecipitation using anti-IHH antibody in
WT and GPC3 TG mice at days 0, 2, and 8 after PHx. B: Ratios of densi-
tometry of bound GPC3 and patched normalized to the amount of IHH
pulled down for a time after PHx in WT and TG mice. C: Western blot of
nuclear GLI1 and smoothened (proteins of HH signaling pathway) in WT and
GPC3 TG mice for a time after PHx. Densitometric analyses of GLI1 (D) and
smoothened (E) normalized to Ponceau stain and b-actin, respectively.
*P < 0.05 versus the corresponding 0 hour time point. yP < 0.05 versus the
corresponding time point in the WT group. zP < 0.05 versus the GP3/IHH
ratio at the same time point.
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Figure 3 IHC staining of GLI1 in WT and GPC3 TG mouse livers.
Representative photomicrographs of GLI1 at days 0, 2, and 8 after PHx.
Original magniﬁcation, 200.
Figure 4 Interaction of GPC3 with CD81. A: Western blot of CD81 and
GPC3 after co-immunoprecipitation using anti-GPC3 antibody in WT and
GPC3 TG mice at days 0, 2, and 8 after PHx. B: Ratios of densitometry of
bound CD81 normalized to the amount of GPC3 pulled down over a time
course after PHx in WT and TG mice. *P < 0.05 versus the corresponding
0 hour time point. yP < 0.05 versus WT at the same time point.
Bhave et alStatistical Analysis
Data are expressed as means  SEM. Statistical differences
were determined by one-way analysis of variance followed
by Tukey’s honestly signiﬁcant difference test to determine
which means were signiﬁcantly different from each other or
from controls using the JMP software version 8 (SAS
Institute Inc., Cary, NC). The criterion for signiﬁcance was
P < 0.05.
Results
GPC3 Affects the HH Signaling Pathway
Pull down using anti-IHH antibody co-immunoprecipitated
GPC3 and patched-1, conﬁrming previous reports that IHH is
a binding partner for GPC3 (Figure 2A). The amount of
GPC3 and patched-1 that bound to IHH at various time points
after PHx normalized to the total amount of IHH pulled down
is shown in Figure 2B. WT mice had a signiﬁcant decrease in
GPC3-IHH binding on day 2 after PHx (peak of proliferation)
compared with day 0, thus making more IHH available
for binding to patched-1 for HH signaling. This ﬁnding156corroborated the increased patched-IHH binding in WT mice
on day 2 (Figure 2, A and B). In contrast to this, GPC3 TG
mice (exhibiting lower hepatocyte proliferation8) failed to
show a decrease in GPC3-IHH binding on day 2 after PHx
compared with day 0. A corresponding increase in patched-
IHH binding on day 2 was not statistically signiﬁcant
(Figure 2B). Moreover, there was signiﬁcantly more GPC3
and less patched-1 bound to IHH in TG mice compared with
WT mice on day 2. These data suggested a failure in induc-
tion of HH signaling pathway in the TG on day 2. Nuclear
GLI1, an effector transcription factor of HH signaling
pathway, was signiﬁcantly induced on day 2 in WT mice
compared with day 0 (Figure 2, C and D). In contrast, the TG
mice had a signiﬁcant decrease in GLI1 compared with day
0 for TG mice and day 2 for WT mice (Figure 2, C and D).
Moreover, GLI1 was also down-regulated in TG mice on day
2 after PHx by IHC (Figure 3). Smoothened (an intracellular
mediator of HH signaling) was unchanged in WT mice after
PHx, whereas GPC3 TG mice had a mild decrease that was
not signiﬁcant (Figure 2, C and E). Overall, the HH signaling
pathway appeared to be up-regulated in WT mice after PHx,
whereas it was down-regulated in the GPC3 TG mice.
GPC3-CD81 Binding Changes After PHx
Conﬁrming previous ﬁndings from our laboratory in
the rat,7 we found that GPC3 binds to CD81 by co-
immunoprecipitation in mouse as well (Figure 4A). The
amount of CD81 bound to GPC3 at various time points after
PHx normalized to the total amount of GPC3 pulled down is
shown in Figure 4B. There was signiﬁcantly more CD81
bound to GPC3 in TG mice compared with WT mice atajp.amjpathol.org - The American Journal of Pathology
Figure 5 Hhex-GST pull-down assay. A: Western blot analysis of pull-
down of Hhex-GST fusion protein conﬁrmed using anti-Hhex antibody.
B: CD81 detected on the same membrane using anti-CD81 antibody, indi-
cating it to be a binding partner for Hhex. C: GST protein detected after
using GST protein instead of HHEX-GST fusion protein for the assay as
a negative control. D: CD81 could not be detected on the same membrane,
conﬁrming the speciﬁcity of CD81 binding to Hhex.
Figure 6 Interaction of CD81 withHhex.A: Western blot of Hhex and CD81
after co-immunoprecipitationusing anti-CD81antibody inWT andGPC3 TGmice
at days 0, 2, and 8 after PHx. B: Ratios of densitometry of bound Hhex
normalized to the amount of CD81 pulled down during a time after PHx in WT
and TG mice. C: Western blot of nuclear Hhex and Ponceau stain as loading
control inWTandGPC3 TGmiceduring timeafter PHx.D: Densitometric analyses
of nuclear Hhex normalized to Ponceau stain. *P < 0.05 versus the corre-
sponding 0 hour time point. yP< 0.05 versus WT mice at the same time point.
Regulation of Liver Growth by GPC3all time points (Figure 4, A and B). Within the group (WT
and TG mice), the amount of CD81 bound to GPC3
signiﬁcantly decreased on day 2 (proliferation peak) and
increased by day 8 (past end of hepatocyte proliferation).
These data support our previous report in rats7 that GPC3
and CD81 binding increases toward the end of hepatocyte
proliferation. Figure 4A shows lower GPC3 in WT and TG
mice on day 8 after PHx. This ﬁnding is most likely due to
unequal loading (loss of GPC3 pulled down during perfor-
mance of the technique) and not because of less absolute
GPC3 expression at this time point. However, because we
are analyzing CD81 bound to pulled down GPC3 (ratio),
lower GPC3 on day 8 does not affect our interpretation.
Yeast Two-Hybrid Assay
Hhex came out as one of the binding partners of CD81
under highest-stringency conditions (YPDA plates with
SD/-Ade/-His/-Leu/-Trp). Other proteins identiﬁed were
secreted phosphoprotein 2, terminal uridyl transferase 1, and
HMG-CoA synthase 2 (mitochondrial). We chose to pursue
Hhex for its role as a transcriptional repressor. To conﬁrm
Hhex as a binding partner for CD81, we performed two
additional techniques: HhEX-GST pull-down assay and co-
immunoprecipitation with CD81.
Hhex-GST Pull-Down Assay
To conﬁrm Hhex as a binding partner for CD81 in mouse
liver, we performed a GST pull-down assay. For the yeast
two-hybrid assay, CD81 cDNA was our bait protein. In the
GST pull-down assay, we used Hhex-GST fusion protein or
GST protein (control) as our bait and incubated it with
pooled whole liver lysate. CD81 came down in the assay,
conﬁrming it as a binding partner (Figure 5, A and B).
Lysates incubated with GST protein were unable to pull-
down CD81 (Figure 5, C and D), conﬁrming that CD81 isThe American Journal of Pathology - ajp.amjpathol.orga speciﬁc binding partner for Hhex and not GST. Thus,
using two completely different techniques and using both
proteins as baits, we were able to show that CD81 and Hhex
are binding partners for each other.
CD81-Hhex Binding Changes After PHx
To study the dynamics of CD81-Hhex binding during liver
regeneration, we performed co-immunoprecipitation for the
two proteins (Figure 6A). The amount of Hhex bound to
CD81 at various time points was normalized to the total157
Bhave et alCD81 pulled down (Figure 6B). In WT mice, less Hhex was
bound to CD81 on day 0 (Figure 6, A and B). There was
a signiﬁcant increase in bound Hhex on day 2 after PHx
followed by its decrease to normal levels by day 8. In stark
contrast to this pattern, in the TG mice, there was signiﬁ-
cantly higher Hhex bound to CD81 to start with on day 0,
which decreased signiﬁcantly on days 2 through 8. To test
whether the amount of Hhex bound to CD81 (near the
membrane) inversely correlated with the amount of nuclear
Hhex (transcriptional repressor), we looked at nuclear Hhex
by Western blot (Figure 6C) normalized to Ponceau stain for
equal loading (Figure 6D). As expected, nuclear Hhex was
signiﬁcantly lower in WT mice on day 2 compared with
day 0. In contrast, it signiﬁcantly increased in TG mice on
day 2 compared with day 0. There was also signiﬁcantly
higher nuclear Hhex in TG versus WT mice at the peak of
proliferation (day 2). These data support our hypothesis that
the binding of CD81 to Hhex might keep it outside the
nucleus and prevent its transcriptional repressor functions.Figure 7 Expression of patched receptor. Western blot for patched
receptor (140 kDa) using goat polyclonal antibody (top) and rabbit poly-
clonal antibody (bottom) on cell lysates from whole livers, hepatocyte
pellet (Hep), and NPC after perfusion of WT mouse livers.Expression of Patched-1 Receptor
Expression of patched-1 by hepatocytes is controversial.22
To test whether hepatocytes express patched-1, we per-
fused WT mouse liver and looked at patched-1 protein
by Western blot analysis in hepatocyte pellet and non-
parenchymal cell pellet (NPC) fraction using two different
antibodies. We were able to detect a clear band with both
the antibodies in whole liver lysates, hepatocyte pellet
lysate, and NPC pellet lysate (Figure 7).Discussion
GPC3 acts as a growth regulator in the absence of
a known signaling domain in the cell membrane. GPC3 TG
mice have inhibited liver regeneration response on day
2 after PHx compared with WT mice as assessed by
Ki-67epositive nuclei.8 Our data indicate at least two
different pathways through which GPC3 regulates growth.
First, it binds to HH ligand (IHH) and down-regulates HH
signaling in liver. Second, it binds to CD81, leading to
decreased CD81-Hhex binding, which in turn causes
nuclear translocation of transcriptional repressor Hhex.
Whether treatment of TG mice with smoothened agonist can
rescue this phenotype at least partly would be an interesting
experiment. Inhibition of Hhex might not result in complete
reversal of growth inhibitory effects of GPC3 because of
GPC3-IHH interactions and functions of Hhex other than
transcriptional repression. To our knowledge, this is the ﬁrst
study describing CD81 and Hhex to be binding partners for
each other. We conﬁrmed this using three different tech-
niques in the present study.
Although our results suggest down-regulation of HH
signaling in the liver as a whole, whether GPC3 can regu-
late HH signaling speciﬁcally in hepatocytes is not clear.158Previous studies have found that hepatocytes are not
responsive to HH signaling because they do not express the
HH receptor patched-1.22 Our data suggest that hepatocytes
express patched-1 (Figure 7). Moreover, hepatocytes express
GLI1 (Figures 2C and 3) and GLI2,10 the transcriptional
effectors of HH signaling. We also saw GLI2 expression in
WT and GPC3 TG mice by Western blot and IHC but did
not see any change in them after PHx (data not shown).
Despite the fact that the GLI family of transcription
factors are recognized as predominantly regulated by HH
signaling, a few other studies have reported that GLI
may also be activated independent of HH-patched-
1esmoothened pathway through TGFb and KRAS in pan-
creatic adenocarcinoma cells.23 Such an event has not been
demonstrated in nonneoplastic cells. GPC3 TG mice have
less GLI1 on day 2 after PHx compared with WT mice
(Figures 2C and 3). This ﬁnding could be partially attributed
to previous ﬁndings from our laboratory indicating more
than threefold down-regulation of TGFb gene in GPC TG
mice compared with WT mice.8
We chose to include GPC3 TG mice in this study to
understand if and how overexpression of GPC3 changed the
mechanisms for its growth regulatory function. Our data
suggest that there were several differences in WT and GPC3
TG mice at baseline (day 0) that changed further after
a regenerative stimulus (PHx). First, along with over-
expression of GPC3 in TG mice, these mice exhibited
a higher level of preparedness for proliferation as evidenced
by increased GLI1 by Western blot and IHC (Figures 2C and
3), suggesting that the pathway is more activated in TG than
in WT mice in resting livers. The HH signaling pathway has
been reported to be involved in epithelial-to-mesenchymal
transition and progenitor cell phenotype.22 We were notajp.amjpathol.org - The American Journal of Pathology
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in these livers by microscopy, which looked pretty
comparable to WT mice. However, we have not looked at
speciﬁc markers of progenitor cells in the livers of GPC3
TG mice at day 0 to conclusively exclude the possibility.
Second, nuclear Hhex (transcriptional repressor) was
signiﬁcantly less in TG mice resting liver compared with
WT mice (Figure 6, C and D), again suggesting more
preparedness for cell division in these TG mice. However,
this preparedness for proliferation did not result in a higher
rate of proliferation at baseline as evidenced by comparable
Ki-67 staining in TG and WT mice at day 0 shown previ-
ously.8 These changes in protein expression in resting livers
of TG mice are suggestive of adaptive changes due to gene
modiﬁcation. However, at day 2 after PHx (proliferation
peak), TG mice were unable to induce the HH pathway
sufﬁciently to mount a compensatory regeneration response
possibly due to changes in GPC3-IHH, GPC3-CD81, and
CD81-Hhex binding (an effect of GPC3 overexpression in
these mice). The upstream factors that might inﬂuence the
observed changes in GPC3 binding to its partners are not
known and worthy of further investigation. This study
demonstrates that changes in protein interactions (demon-
strated by ratios of bound protein normalized to pulled-
down protein), independent of their absolute levels, might
inﬂuence regulation of growth.
Even though our study presents evidence that the HH
system is operative in hepatocytes, our studies with whole
liver homogenates encompass the entire population of
hepatic cells (hepatocytes and nonparenchymal cells). In
addition to the potential effects on hepatocytes, binding of
GPC3 to HH ligands in the extracellular space can decrease
the availability of HH ligands for patched-1 binding in HH
responsive cells (stellate or endothelial) other than hepato-
cytes, also leading to an overall down-regulation of HH
signaling pathway in the liver. Because hepatocyte prolif-
eration after PHx is dependent on hepatocyte growth factor
made by stellate cells, which are known to be HH respon-
sive, GPC3-HH binding could also affect hepatocyte
proliferation in an indirect (paracrine) mechanism.References
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